1.Progress in diagnosis and treatment of mantle cell lymphoma
Gege CHEN ; Jumei SHI ; Yiwen ZHANG
Journal of Leukemia & Lymphoma 2016;25(10):637-640
Mantle cell lymphoma (MCL) is a group of highly aggressive non-Hodgkin lymphoma (NHL) in small B-cell lymphoma, accounting for 6 % of NHL incidence. MCL is characterized with its concealed onset, strong aggression, high malignancy and poor prognosis. Therefore, more attention should be paid to the diagnosis and differential diagnosis of MCL in clinic. Recently, diagnostic models of molecular pathology, researches on cyclin D1 protein negative MCL, staging prognosis and stratification treatment of MCL are worthy of attention.
2.Checkpoint inhibition in myeloma
Yiwen ZHANG ; Dandan YU ; Fenghuang ZHAN ; Jumei SHI
Journal of Leukemia & Lymphoma 2017;26(2):78-82
Myeloma is a malignancy associated with significant immune dysfunction imparted by both the disease itself as well as many of the immunosuppressive therapies that have been used in the past.The growing body of preclinical data regarding immunoregulatory mechanisms that appear active in myeloma has begun to be translated to clinical trials targeting these signalling axes.This review summarized the current understanding of the basic biology of several immune checkpoint pathways that may be important in myeloma and provide an up-to-date overview of recent and ongoing clinical trials of immune checkpoint inhibitors in myeloma.Finally,several current challenges and possible future direction of immune checkpoint blockade in myeloma will be reviewed.
4. Effect of chronic hepatitis B virus DNA negative transformation and HBsAg clearance on the occurrence of hepatocellular carcinoma
Jialing ZHOU ; Bingqiong WANG ; Yiwen SHI ; Hong YOU
Chinese Journal of Hepatology 2019;27(11):831-833
Achieving HBV DNA negative transformation and HBsAg clearance with effective antiviral therapy can reduce the incidence of HCC, but some patients are still at risk of developing HCC. Therefore, screening high-risk patients for close monitoring is essential to reduce the incidence of HCC. This paper reviews the occurrence of HCC, risk factors and risk prediction models of HBV DNA negative transformation and HBsAg clearance, and provides a basis for screening and follow-up management of high-risk group of HCC with chronic hepatitis B.
5.Application value of imaging diagnosis in nonalcoholic fatty liver disease
Jia HONG ; Yiwen SHI ; Xiaoning WU
Journal of Clinical Hepatology 2018;34(12):2698-2701
Nonalcoholic fatty liver disease (NAFLD) is a chronic disease with complex lesions, and it is difficult to determine the clinical stage. Liver biopsy is still the gold standard for the diagnosis of NAFLD; however, its clinical application is limited by various factors. Therefore, noninvasive methods for the accurate diagnosis of NAFLD are research hotspots at present. Imaging examinations help to achieve qualitative and quantitative evaluations of hepatic steatosis and fibrosis and thus has a promising future in clinical practice. This article summarizes the research advances in the imaging diagnosis of nonalcoholic fatty liver disease in recent years.
6.Therapeutic developments in metabolic dysfunction-associated fatty liver disease
Chinese Medical Journal 2022;135(9):1009-1018
Metabolic dysfunction-associated fatty liver disease (MAFLD) has become one of the most prevalent chronic liver diseases worldwide, bringing risk of multiorgan disfunctions including cardiovascular events, complications of cirrhosis, and even malignance. In terms of health burden management, screening patients with high risk of MAFLD and providing individual comprehensive treatment is critical. Although there are numerous agents entering clinical trials for MAFLD treatment every year, there is still no effective approved drug. The nomenclature of MAFLD highlighted the concomitant metabolic disorders and obesity. MAFLD patients with type 2 diabetes had higher risk of developing liver cirrhosis and cancer, and would benefit from anti-hyperglycemic agents; overweight and obese patients may benefit more from weight loss therapies; for patients with metabolic syndrome, individual comprehensive management is needed to reduce the risk of adverse outcomes. In this review, we introduced the current status and advances of the treatment of MAFLD based on weight loss, improving insulin resistance, and management of cardiometabolic disorders, in order to provide individualized therapy approaches for patients with MAFLD.
7.Therapeutic strategies for patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid
Journal of Clinical Hepatology 2017;33(11):2101-2104
In recent years,ursodeoxycholic acid is commonly used for the treatment of primary biliary cholangitis (PBC);however,the growing number of PBC patients and the occurrence of suboptimal response and treatment intolerance pose a great challenge to treatment regimens.The approval of the new drug obeticholic acid brings hope to PBC patients,and a combination of fibrates also has a promising future.More studies are in progress.Although new drugs,such as monoclonal antibody,fibroblast growth factor 19,and sodium-dependent bile acid transporter inhibitor,have limited efficacy data,they provide new directions for the treatment of PBC.With the help of individualized follow-up and stratified therapy,the management of PBC patients will enter a new stage.
9.Effect of selective brain hypothermia on SUMOylation of cerebral cortex during cerebral ischemia-reperfusion in rats
Yiwen JIANG ; Gaofeng ZHANG ; Huailong CHEN ; Fei SHI ; Mingshan WANG
Chinese Journal of Anesthesiology 2018;38(6):664-667
Objective To evaluate the effect of selective brain hypothermia on small ubiquitin-like modifier (SUMO)ylation of cerebral cortex during cerebral ischemia-reperfusion (I/R) in rats.Methods A total of 120 healthy clean-grade male Sprague-Dawley rats,aged 8 weeks,weighing 200-250 g,were divided into 4 groups (n=30 each) by a random number table method:sham operation group (group S),group I/R,selective brain hypothermia group (group H) and 37 ℃ normal saline group (group N).Rats were anesthetized with 10% chloral hydrate 3 ml/kg.Cerebral ischemia was induced by middle cerebral artery occlusion using a nylon thread with rounded tip inserted into the right internal carotid artery and advanced cranially until resistance was met.The right middle cerebral artery was occluded for 2 h followed by reperfusion in group I/R.10-13 ℃ normal saline was infused at the rate of 100 ml · kg-1 · h-1 for 20 min starting from the time point immediately after removing the nylon thread in group H.37 ℃ normal saline was infused instead at the same rate for 20 min in N group.The neurological deficit were assessed and scored at 6,24 and 48 h after reperfusion.The cerebral cortex on ischemic side was then removed for determination of cell apoptosis (by TUNEL) and expression of SUMO sepcific proteases 3 (SENP3) and SUMO2/3-conjugated protein (by Western blot).The apoptotic rate was calculated.Results Compared with group S,the neurological deficit score and apoptosis rate were significantly increased,and the expression of SUMO2/3-conjugated protein was up-regulated at each time point after reperfusion in the other three groups (P<0.05),and the expression of SENP3 was significantly up-regulated in I/R and N groups and down-regulated in group H (P<0.01).Compared with group I/R,the neurological deficit score and apoptosis rate were significantly decreased,the expression of SUMO2/3-conjugated protein was up-regulated,and the expression of SENP3 was down-regulated in group H (P<0.05).Conclusion The mechanism by which selective brain hypothermia reduces cerebral I/R injury is related to enhancing SUMOylation of cerebral cortex in rats.
10. Progress of individualized treatment in Waldenström macroglobulinemia
Jun HOU ; Yiwen ZHANG ; Xiaosong WU ; Jumei SHI
Journal of Leukemia & Lymphoma 2018;27(4):193-197
Waldenström macroglobulinemia (WM) is a rare lymphoma without a curable treatment method, which is characterized by MYD88 and CXCR4 gene mutations. The study on clinical manifestations, the pathological and genomic features has led to a series of promising clinical protocols. This article reviews the safety and efficacy of drugs including alkylating agents, proteasome inhibitors, monoclonal antibodies, and Bruton tyrosine kinase (BTK) inhibitors in WM patients combined with the latest research of the individualized treatment for WM at the 59th American Society of Hematology (ASH) Annual Meeting, so as to analyze the feasibility of basic genomic treatment and current integrated regimens for WM.